Providing a diverse range of perspectives from bullish to bearish, 14 analysts have published ratings on Intra-Cellular Therapies (NASDAQ:ITCI) in the last three months.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 8 | 5 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 4 | 2 | 1 | 0 | 0 |
| 2M Ago | 2 | 2 | 0 | 0 | 0 |
| 3M Ago | 1 | 1 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Intra-Cellular Therapies, presenting an average target of $88.86, a high estimate of $103.00, and a low estimate of $77.00. Marking an increase of 10.55%, the current average surpasses the previous average price target of $80.38.
Interpreting Analyst Ratings: A Closer Look
The...
ログインすると全部閲覧できます。
ログイン
